Individualized dosing with KYNMOBI® (apomorphine HCl)1

5 strengths available to help find your patient’s optimal dose

  • KYNMOBI is available in 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg dose strengths
    • The maximum single dose of KYNMOBI is 30 mg
  • KYNMOBI should be taken no more than 5 times a day
  • Doses should be separated by at least 2 hours
    • If a single dose of KYNMOBI is ineffective for a particular OFF episode, a second dose should not be taken for that OFF episode. The efficacy or safety of administering a second dose for a single OFF episode has not been studied
  • An antiemetic (eg, trimethobenzamide 300 mg) is recommended, beginning 3 days prior to the initial dose of KYNMOBI but generally no longer than 2 months after the initial dose, given the incidence of nausea and vomiting
KYNMOBI can be used for any OFF episode at any time of day, up to 5 times a day, regardless of when other PD medications are taken1,2

Watch a short video to see how KYNMOBI is administered

Find out how to
prescribe KYNMOBI

References: 1. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; May 2020. 2. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomized, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144. 3. Hui JS, Fox SH, Neeson W, et al. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. Parkinsonism Relat Disord. 2020;79:110-116. 4. Data on file. Sunovion Pharmaceuticals Inc. 5. Ellenbogen AL, Nicholas AP, Hauser RA, Bhargava P, Pappert E, Navia B. Apomorphine sublingual film for the treatment of “off” episodes in patients with Parkinson’s disease: impact of concomitant antiemetics and dopamine agonists on nausea and vomiting. Poster presented at: International Parkinson and Movement Disorder Society Virtual Congress 2020; September 12-16, 2020; Milwaukee, WI. 6. U.S. National Library of Medicine. Study NCT02542696. Accessed April 20, 2021. https://clinicaltrials.gov/ct2/show/NCT02542696.

Top

Thank you for registering at KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.